VACCINEX, INC.·4

Feb 9, 4:34 PM ET

Zauderer Maurice 4

4 · VACCINEX, INC. · Filed Feb 9, 2024

Insider Transaction Report

Form 4
Period: 2024-02-08
Zauderer Maurice
DirectorPresident and CEO10% Owner
Transactions
  • Award

    Common Stock

    2024-02-08$0.72/sh+413,793$300,0001,393,392 total(indirect: By Vaccinex (Rochester), L.L.C.)
  • Award

    Warrant (Right to Buy)

    2024-02-08$0.72/sh+413,793$300,000413,793 total(indirect: By Vaccinex (Rochester), L.L.C.)
    Exercise: $1.00From: 2024-02-08Exp: 2029-02-08Common Stock (413,793 underlying)
Holdings
  • Common Stock

    22,116
  • Stock Option (Right to Buy)

    Exercise: $223.50Exp: 2024-06-30Common Stock (172 underlying)
    172
  • Stock Option (Right to Buy)

    Exercise: $100.20Exp: 2025-02-24Common Stock (1,893 underlying)
    1,893
  • Stock Option (Right to Buy)

    Exercise: $19.35Exp: 2032-04-01Common Stock (1,866 underlying)
    1,866
  • Stock Option (Right to Buy)

    Exercise: $223.50Exp: 2024-03-31Common Stock (172 underlying)
    172
  • Stock Option (Right to Buy)

    Exercise: $106.50Exp: 2025-12-23Common Stock (221 underlying)
    221
  • Stock Option (Right to Buy)

    Exercise: $64.35Exp: 2024-03-14Common Stock (1,333 underlying)
    1,333
  • Common Stock

    (indirect: By Trust)
    14,214
  • Common Stock

    (indirect: By Trust)
    14,145
  • Warrant (Right to Buy)

    (indirect: By Vaccinex (Rochester), L.L.C.)
    Exercise: $2.34From: 2023-11-02Exp: 2028-11-02Common Stock (136,752 underlying)
    136,752
  • Warrant (Right to Buy)

    (indirect: By Vaccinex (Rochester), L.L.C.)
    Exercise: $1.00From: 2023-10-03Exp: 2028-10-03Common Stock (500,000 underlying)
    500,000
  • Stock Option (Right to Buy)

    Exercise: $43.95Exp: 2031-04-02Common Stock (933 underlying)
    933
  • Stock Option (Right to Buy)

    Exercise: $6.59Exp: 2028-03-30Common Stock (3,733 underlying)
    3,733
Footnotes (7)
  • [F1]Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
  • [F2]Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  • [F3]Exercisable in full as of the date of this report.
  • [F4]This option vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date, except as otherwise provided in the award notice.
  • [F5]This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
  • [F6]This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
  • [F7]This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES